Postprint online available 10/2019 Open Access Green as soon as is submitted to ZB.
Targeting innate and adaptive immune responses to cure chronic HBV infection.
Gastroenterology 156, 325-337 (2018)
Fewer than 1% of chronic hepatitis B virus infections per year are cured with antiviral treatment. This creates a need for long-term treatment, which poses challenges for patients and health systems. Because cure is accompanied by recovery of antiviral immunity, a combination of direct-acting antiviral agents and immunotherapy are likely to be required. Extensive efforts have been made to identify determinants of the failed immune response to hepatitis B virus in patients with chronic infection. We review mechanisms of immune dysfunction in patients with chronic hepatitis B virus infection, immunotherapy strategies in development, and the challenges associated with successful implementation of immunotherapy.
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Keywords Drug ; Hbsag ; Vaccine ; Inflammation; Hepatitis-b-virus; Cd8(+) T-cells; Adoptive Transfer; Viral-hepatitis; Surface-antigen; Hepatocellular-carcinoma; Programmed Death-1; Liver; Replication; Hepatocytes
Institute(s) Institute of Virology (VIRO)